Covered Stocks

Kevin Kedra

Work Rating Distribution Performance Price Targets & Ratings Chart

Analyst Kevin Kedra works at GABELLI and is focused on the Healthcare sector with 19 price targets and ratings documented since 2016 spanning on 3 stocks. Analyst's average stock valuation to be materialised ratio is 75% with an average time for price targets to be met of 155.5 days.

Most recent stock forecast was given on LXRX, Lexicon Pharmaceuticals, Inc at 15-Jan-2021.

Kevin Kedra best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS, INC).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS, INC) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.

Average potential price target upside

Currently, out of the existing stock ratings of Kevin Kedra - 1115 which are a Buy (47.27%), 929 which are a Hold (39.38%), 315 which are a Sell (13.35%)

LXRX ELAN TTPH

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

18

8 months 28 days ago

5/14 (35.71%)

$7.93 (191.40%)

39

Hold

6

$3.68 (158.62%)

3

2 years 18 days ago

3/7 (42.86%)

$5.92 (73.77%)

59

Hold

2

$-0.32 (-13.79%)

34

2 years 2 months ago

2/11 (18.18%)

$15.78 (153.81%)

409

Hold

7

$4.78 (215.32%)

2 years 2 months ago

3/3 (100%)

$1.33 (13.05%)

55

Hold

2 years 2 months 14 days ago

1/1 (100%)

$0.8 (36.36%)

7

Show more analysts
LXRX ELAN TTPH